| Literature DB >> 33057358 |
Niloofar Khairkhah1,2, Mohammad Reza Aghasadeghi1, Ali Namvar2, Azam Bolhassani1.
Abstract
The causative agent of severe acute respiratory syndrome (SARS) reported by the Chinese Center for Disease Coene">ntrol (China CDC) has been identified as a novelEntities:
Mesh:
Substances:
Year: 2020 PMID: 33057358 PMCID: PMC7561160 DOI: 10.1371/journal.pone.0240577
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The selected LBL* epitopes of SARS-CoV-2 based on binding affinity.
| Protein Name | Position | Epitope Sequence | Antibody Class Prediction |
|---|---|---|---|
| S | 1133–1172 | VNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGI | IgG |
| 440–501 | NLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN | IgG | |
| 59–81 | FSNVTWFHAIHVSGTNGTKRFDN | IgG | |
| 304–322 | KSFTVEKGIYQTSNFRVQP | IgA | |
| N | 232–269 | SKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYN | IgG |
| 164–216 | GTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGD | IgG | |
| 1–51 | MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTAS | IgG | |
| 361–390 | KTFPPTEPKKDKKKKADETQALPQRQKKQQ | IgG |
*Linear B lymphocyte
The selected CTL* epitopes of SARS-CoV-2 based on binding affinity.
| Protein Name | Position | Epitope Sequence | No. of Alleles | NetMHCpan Average Rank Scores | Conservancy | Allergenicity |
|---|---|---|---|---|---|---|
| S | 27–37 | YTNSFTRGVYY | 12 | 0.67 | S:100% | Non-allergen |
| 686–696 | VASQSIIAYTM | 12 | 0.69 | S:100% | Non-allergen | |
| 191–199 | FVFKNIDGY | 10 | 0.66 | S:100% | Non-allergen | |
| 1051–1061 | FPQSAPHGVVF | 10 | 1.08 | S:100% | Non-allergen | |
| 257–265 | WTAGAAAYY | 9 | 0.44 | S:100% | Non-allergen | |
| 603–611 | TSNQVAVLY | 9 | 0.44 | S:100% | Non-allergen | |
| 868–876 | MIAQYTSAL | 9 | 0.61 | S:100% | Non-allergen | |
| 161–169 | SANNCTFEY | 8 | 0.96 | S:100% | Non-allergen | |
| 360–368 | CVADYSVLY | 8 | 0.48 | S:100% | Non-allergen | |
| 1094–1102 | FVSNGTHWF | 8 | 0.69 | S:100% | Non-allergen | |
| N | 103–113 | LSPRWYFYYLG | 10 | 1.04 | S:100% | Non-allergen |
| 304–313 | AQFAPSASAF | 8 | 0.87 | S:100% | Non-allergen | |
| 47–55 | NTASWFTAL | 6 | 0.70 | S:100% | Non-allergen | |
| 264–273 | TKAYNVTQAF | 6 | 0.90 | S:100% | Non-allergen | |
| 52–60 | FTALTQHGK | 5 | 0.64 | S:100% | Non-allergen | |
| M | 36–46 | FAYANRNRFLY | 13 | 1.23 | S:100% | Non-allergen |
| 168–180 | TVATSRTLSYY | 9 | 0.89 | S:100% | Non-allergen | |
| 195–204 | YSRYRIGNYK | 9 | 0.31 | S:100% | Non-allergen | |
| 90–99 | MWLSYFIASF | 7 | 1.05 | S:100% | Non-allergen | |
| 102–111 | FARTRSMWSF | 7 | 0.59 | S:100% | Non-allergen |
* Cytotoxic T lymphocyte
** Lower rates show better binding affinity
*** There are four clades of SARS-CoV-2 according to GISAID database
The selected HTL epitopes of SARS-CoV-2 based on binding affinity.
| Protein Name | Position | Epitope Sequence | No. of Alleles | NetMHCpan Average Rank Scores | Conservancy | Allergenicity | IFN-gamma prediction | IL-10 prediction |
|---|---|---|---|---|---|---|---|---|
| S | 196–231 | NIDGYFKIYSKHTPINLVRDLPQGFS | 25 | 4.29 | S:100% | Non-allergen | Positive | Positive |
| 303–323 | LKSFTVEKGIYQTSNFRVQPT | 25 | 3.96 | S:100% | Non-allergen | Positive | Negative | |
| 313–330 | YQTSNFRVQPTESIVRFP | 25 | 3.17 | S:100% | Non-allergen | Positive | Positive | |
| 1009–1030 | TQQLIRAAEIRASANLAATKMS | 25 | 3.89 | S:100% | Non-allergen | Positive | Positive | |
| 32–53 | FTRGVYYPDKVFRSSVLHSTQD | 24 | 4.45 | S:100% | Non-allergen | Positive | Positive | |
| 1057–1074 | PHGVVFLHVTYVPAQEKN | 22 | 5.7 | S:100% | Non-allergen | Positive | Positive | |
| 689–704 | SQSIIAYTMSLGAENS | 21 | 5.2 | S:100% | Non-allergen | Positive | Positive | |
| 801–817 | NFSQILPDPSKPSKRSF | 20 | 3.51 | S:100% | Non-allergen | Negative | Positive | |
| 1110–1126 | YEPQIITTDNTFVSGNC | 19 | 3.19 | S:100% | Non-allergen | Negative | Positive | |
| 114–130 | TQSLLIVNNATNVVIKV | 19 | 5.37 | S:100% | Non-allergen | Positive | Positive | |
| N | 328–349 | GTWLTYTGAIKLDDKDPNFKDQ | 25 | 4.5 | S:100% | Non-allergen | Positive | Negative |
| 126–143 | NKDGIIWVATEGALNTPK | 24 | 3.85 | S:100% | Non-allergen | Positive | Negative | |
| 342–361 | KDPNFKDQVILLNKHIDAYK | 24 | 4.39 | S:100% | Non-allergen | Positive | Positive | |
| 48–63 | NTASWFTALTQHGKED | 23 | 3.24 | S:100% | Non-allergen | Positive | Negative | |
| 167–181 | LPKGFYAEGSRGGSQ | 23 | 2 | S:100% | Non-allergen | Negative | Negative | |
| 405–419 | KQLQQSMSSADSTQA | 22 | 3.58 | S:100% | Non-allergen | Negative | Negative | |
| M | 198–217 | RYRIGNYKLNTDHSSSSDNI | 22 | 4.76 | S:100% | Non-allergen | Positive | Negative |
| 173–191 | SRTLSYYKLGASQRVAGDS | 20 | 4.53 | S:100% | Non-allergen | Positive | Negative | |
| 107–128 | RSMWSFNPETNILLNVPLHGTI | 19 | 6.02 | S:100% | Non-allergen | Positive | Negative | |
| 163–181 | DLPKEITVATSRTLSYYKL | 17 | 3.57 | S:100% | Non-allergen | Positive | Negative |
*lower rates show better binding affinity
Proteasomal cleavage and TAP transport efficiency scores of MHC-I predicted epitopes.
| Protein Name | Position | Epitope Sequence | Proteasomal C -terminal cleavage Score | TAP transport efficiency Score | Epitope identification Score |
|---|---|---|---|---|---|
| 27–37 | YTNSFTRGVYY | 1.43 | 0.96 | 1.73 | |
| 686–696 | VASQSIIAYTM | 1.49 | 0.93 | 1.73 | |
| 191–199 | FVFKNIDGY | 1.75 | 0.94 | 2.03 | |
| 1051–1061 | FPQSAPHGVVF | 0.98 | 0.93 | 1.18 | |
| 257–265 | WTAGAAAYY | 2.85 | 0.94 | 3.14 | |
| 603–611 | TSNQVAVLY | 2.87 | 0.95 | 3.07 | |
| 868–876 | MIAQYTSAL | 1.04 | 0.93 | 1.33 | |
| 161–169 | SANNCTFEY | 2.07 | 0.92 | 2.36 | |
| 360–368 | CVADYSVLY | 2.27 | 0.97 | 2.56 | |
| 1094–1102 | FVSNGTHWF | 1.46 | 0.86 | 1.72 | |
| 103–113 | LSPRWYFYYLG | 2.05 | 0.96 | 2.34 | |
| 304–313 | AQFAPSASAF | 1.06 | 0.66 | 1.31 | |
| 47–55 | NTASWFTAL | 1.08 | 0.94 | 1.27 | |
| 264–273 | TKAYNVTQAF | 1.01 | 0.94 | 1.30 | |
| 52–60 | FTALTQHGK | 0.80 | 0.72 | 0.92 | |
| 36–46 | FAYANRNRFLY | 1.40 | 0.95 | 1.69 | |
| 168–180 | TVATSRTLSYY | 2.31 | 0.96 | 2.61 | |
| 195–204 | YSRYRIGNYK | 1.36 | 0.84 | 1.64 | |
| 90–99 | MWLSYFIASF | 0.66 | 0.97 | 0.96 | |
| 102–111 | FARTRSMWSF | 1.10 | 0.95 | 1.38 |
*Higher rates show better quality of proteasomal cleavage
** Higher rates show better quality of tap transport efficiency
*** Higher rates show better quality of epitope identification
Population coverage of putative SARS-CoV-2 CTL epitopes.
| Area | S27-37 | S686-696 | S191-199 | S1051-1061 | S257-265 | S603-611 | S868-876 | S161-169 | S360-368 | S1094-1102 | N103-113 | N304-313 | N47-55 | N264-273 | N52-60 | M36-46 | M168-180 | M195-204 | M90-99 | M102-111 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.3% | 61.19% | 47.7% | 42.84% | 45.43% | 45.43% | 47.79% | 41.35% | 41.35% | 37.02% | 39.4% | 33.9% | 31.58% | 38.38% | 27.68% | 46.0% | 43.11% | 34.13% | 25.22% | 30.74% | |
| 69.68% | 67.18% | 54.97% | 51.17% | 50.59% | 50.59% | 54.01% | 44.19% | 44.19% | 48.33% | 47.25% | 27.24% | 27.26% | 29.76% | 31.08% | 53.0% | 48.86% | 41.54% | 28.22% | 28.53% | |
| 68.17% | 59.86% | 55.61% | 54.86% | 55.61% | 55.61% | 60.36% | 55.49% | 53.53% | 74.58% | 78.7% | 82.83% | 31.06% | 70.63% | 32.55% | 84.27% | 54.94% | 45.63% | 71.67% | 35.38% | |
| 93.95% | 80.28% | 77.35% | 71.73% | 73.88% | 73.88% | 79.54% | 73.47% | 73.45% | 61.27% | 76.7% | 71.17% | 52.65% | 64.39% | 64.85% | 85.33% | 70.88% | 70.14% | 59.55% | 50.55% | |
| 76.03% | 73.45% | 57.9% | 50.94% | 55.03% | 55.03% | 59.15% | 52.23% | 52.0% | 52.87% | 55.62% | 44.7% | 30.4% | 34.85% | 36.01% | 57.8% | 50.85% | 46.2% | 37.72% | 29.94% | |
| 84.8% | 69.76% | 64.08% | 57.57% | 61.39% | 61.39% | 70.66% | 59.51% | 59.28% | 57.58% | 69.4% | 67.35% | 38.65% | 57.07% | 44.89% | 75.68% | 57.57% | 52.73% | 51.7% | 40.09% | |
| 73.97% | 68.15% | 66.77% | 37.1% | 66.51% | 66.51% | 38.22% | 63.48% | 63.43% | 50.44% | 73.37% | 77.42% | 13.17% | 46.14% | 52.93% | 76.81% | 65.94% | 61.92% | 41.39% | 18.03% | |
| 63.86% | 58.32% | 54.78% | 34.54% | 54.21% | 54.21% | 31.12% | 52.96% | 52.96% | 66.01% | 84.26% | 83.22% | 21.79% | 59.46% | 50.2% | 86.64% | 52.61% | 51.88% | 60.32% | 17.61% | |
| 64.94% | 72.02% | 57.59% | 49.1% | 55.81% | 55.81% | 44.82% | 53.25% | 53.25% | 50.83% | 58.64% | 46.87% | 28.43% | 33.15% | 41.9% | 60.92% | 50.64% | 50.62% | 37.25% | 29.34% | |
| 56.97% | 45.93% | 40.8% | 25.13% | 37.66% | 37.66% | 36.75% | 36.75% | 36.75% | 39.03% | 44.64% | 52.03% | 16.62% | 37.72% | 31.08% | 57.06% | 27.16% | 34.24% | 36.7% | 14.41% | |
| 77.05% | 73.24% | 71.64% | 46.92% | 70.83% | 70.83% | 38.84% | 67.75% | 67.75% | 54.67% | 67.42% | 66.54% | 29.6% | 43.15% | 59.67% | 72.8% | 55.62% | 65.66% | 37.59% | 27.3% | |
| 66.67% | 62.24% | 58.2% | 35.31% | 55.92% | 55.92% | 28.83% | 48.97% | 48.97% | 57.94% | 77.29% | 82.1% | 17.1% | 53.25% | 43.57% | 80.89% | 52.67% | 47.52% | 51.06% | 21.82% | |
| 77.27% | 66.35% | 59.6% | 45.9% | 56.9% | 56.9% | 54.88% | 54.49% | 54.49% | 48.92% | 58.54% | 51.82% | 29.33% | 32.89% | 47.47% | 63.53% | 51.56% | 51.97% | 38.63% | 29.55% | |
| 70.28% | 74.43% | 58.96% | 53.85% | 56.47% | 56.47% | 57.29% | 51.92% | 51.92% | 48.96% | 55.22% | 47.07% | 38.36% | 43.67% | 33.19% | 61.05% | 55.9% | 41.03% | 41.74% | 42.38% | |
| 80.64% | 74.78% | 63.01% | 56.85% | 59.44% | 59.44% | 64.77% | 56.07% | 56.07% | 54.84% | 64.26% | 61.14% | 41.35% | 54.32% | 47.92% | 73.47% | 55.9% | 50.81% | 49.62% | 42.73% | |
Population coverage of putative SARS-CoV-2 HTL epitopes.
| Area | S196-231 | S303-323 | S313-330 | S1009-1030 | S32-53 | S1057-1074 | S689-704 | S801-817 | S1110-1126 | S114-130 | N328-349 | N126-143 | N342-361 | N48-63 | N167-181 | N405-419 | M198-217 | M173-191 | M107-128 | M163-181 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.33% | 75.33% | 75.33% | 75.33% | 71.52% | 59.02% | 59.34% | 60.66% | 64.38% | 66.12% | 75.33% | 67.04% | 74.78% | 66.93% | 64.03% | 56.8% | 61.37% | 70.37% | 59.27% | 65.04% | |
| 81.34% | 81.34% | 81.34% | 81.34% | 76.57% | 65.54% | 58.27% | 68.08% | 62.42% | 65.07% | 81.34% | 73.27% | 80.55% | 74.6% | 69.31% | 56.04% | 65.89% | 74.4% | 62.42% | 64.24% | |
| 86.93% | 86.93% | 86.93% | 86.93% | 84.15% | 84.31% | 81.62% | 62.84% | 79.63% | 73.29% | 86.93% | 86.13% | 80.46% | 79.92% | 82.21% | 77.93% | 72.87% | 72.62% | 67.69% | 66.34% | |
| 93.54% | 93.54% | 93.54% | 93.54% | 92.38% | 81.75% | 78.89% | 72.95% | 86.86% | 87.15% | 93.54% | 90.14% | 93.42% | 77.57% | 84.85% | 76.43% | 87.88% | 91.26% | 80.17% | 81.71% | |
| 88.26% | 88.26% | 88.26% | 88.26% | 87.65% | 74.7% | 72.59% | 73.18% | 80.37% | 82.82% | 88.26% | 85.14% | 87.95% | 71.69% | 78.01% | 75.59% | 83.78% | 83.49% | 68.5% | 76.74% | |
| 94.75% | 94.75% | 94.75% | 94.75% | 93.79% | 84.42% | 82.17% | 77.86% | 88.13% | 88.84% | 94.75% | 92.18% | 94.5% | 73.57% | 86.73% | 79.13% | 89.33% | 93.19% | 83.03% | 83.13% | |
| 68.85% | 68.85% | 68.85% | 68.85% | 65.35% | 63.16% | 60.58% | 47.01% | 62.19% | 54.36% | 68.85% | 66.94% | 65.74% | 78.32% | 61.48% | 54.28% | 53.05% | 59.87% | 54.07% | 56.44% | |
| 74.82% | 74.82% | 74.82% | 74.82% | 69.27% | 73.93% | 62.41% | 62.75% | 61.98% | 58.06% | 74.82% | 74.55% | 68.85% | 56.81% | 68.59% | 54.01% | 64.28% | 53.78% | 52.62% | 43.72% | |
| 52.11% | 52.11% | 52.11% | 52.11% | 52.11% | 8.42% | 31.28% | 50.86% | 51.56% | 50.86% | 52.11% | 32.76% | 52.11% | 66.55% | 31.28% | 32.76% | 31.28% | 52.11% | 30.61% | 52.11% | |
| 76.19% | 76.19% | 76.19% | 76.19% | 75.35% | 69.22% | 68.04% | 62.65% | 58.82% | 68.62% | 76.19% | 73.99% | 67.94% | 31.28% | 70.7% | 68.41% | 68.85% | 71.95% | 65.09% | 54.89% | |
| 88.43% | 88.43% | 88.43% | 88.43% | 87.25% | 77.38% | 75.43% | 66.62% | 77.06% | 82.25% | 88.43% | 84.78% | 88.0% | 68.74% | 80.41% | 71.04% | 82.52% | 85.41% | 71.07% | 79.51% | |
| 67.66% | 67.66% | 67.66% | 67.66% | 65.26% | 62.42% | 56.06% | 50.07% | 59.47% | 50.67% | 67.66% | 67.25% | 62.15% | 73.82% | 60.3% | 53.94% | 54.69% | 56.91% | 49.7% | 51.81% | |
| 58.07% | 58.07% | 58.07% | 58.07% | 57.31% | 48.2% | 44.41% | 45.91% | 48.46% | 50.87% | 58.07% | 54.83% | 57.15% | 56.04% | 50.87% | 45.49% | 53.64% | 52.81% | 43.09% | 43.57% | |
| 84.27% | 84.27% | 84.27% | 84.27% | 83.28% | 75.29% | 72.9% | 71.93% | 64.44% | 72.66% | 84.27% | 79.83% | 83.27% | 48.87% | 79.11% | 70.05% | 73.8% | 78.54% | 60.66% | 69.82% | |
| 77.4% | 77.4% | 77.4% | 77.4% | 74.21% | 69.63% | 62.33% | 52.95% | 64.29% | 64.15% | 77.4% | 73.64% | 76.45% | 77.74% | 70.24% | 59.75% | 67.69% | 72.67% | 65.6% | 61.47% | |
Interaction similarity scores of the selected CTL epitopes using GalexyPepDock flexible docking server.
| Protein | Epitope | HLA A0101 | HLA A0201 | HLA A0301 | HLA A2402 | HLA A1101 | HLA B0702 | HLA B0801 | HLA B2705 | HLA B3501 | HLA B5101 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 | 192 | 184 | 172 | 181 | 186 | 199 | 175 | 219 | 202 | 188.0 | ||
| 195 | 170 | 153 | 160 | 158 | 171 | 167 | 168 | 213 | 185 | 174.0 | ||
| 188 | 209 | 195 | 187 | 197 | 219 | 237 | 206 | 214 | 191 | 204.3 | ||
| 151 | 181 | 165 | 178 | 159 | 170 | 189 | 176 | 201 | 190 | 176.0 | ||
| 203 | 231 | 223 | 190 | 216 | 201 | 192 | 207 | 232 | 212 | 210.7 | ||
| 157 | 163 | 152 | 170 | 151 | 170 | 158 | 171 | 216 | 188 | 169.6 | ||
| 174 | 201 | 187 | 206 | 200 | 203 | 199 | 195 | 242 | 225 | 203.2 | ||
| 205 | 266 | 239 | 237 | 220 | 219 | 227 | 219 | 229 | 225 | 228.6 | ||
| 177 | 216 | 189 | 204 | 179 | 215 | 243 | 200 | 227 | 258 | 210.8 | ||
| 199 | 207 | 189 | 217 | 208 | 235 | 256 | 221 | 220 | 201 | 215.3 | ||
| 210 | 232 | 202 | 268 | 213 | 213 | 236 | 211 | 253 | 226 | 226.4 | ||
| 171 | 231 | 204 | 219 | 185 | 197 | 214 | 187 | 191 | 195 | 199.4 | ||
| 195 | 201 | 196 | 260 | 198 | 211 | 249 | 204 | 200 | 215 | 212.9 | ||
| 164 | 201 | 185 | 191 | 180 | 209 | 188 | 207 | 251 | 223 | 199.9 | ||
| 154 | 176 | 171 | 215 | 170 | 180 | 215 | 178 | 219 | 206 | 188.4 | ||
| 153 | 189 | 168 | 192 | 174 | 189 | 177 | 185 | 187 | 181 | 179.5 | ||
| 167 | 186 | 166 | 170 | 176 | 206 | 232 | 191 | 188 | 176 | 185.8 | ||
| 217 | 244 | 237 | 204 | 237 | 262 | 247 | 254 | 300 | 278 | 248 | ||
| 142 | 186 | 151 | 207 | 160 | 168 | 158 | 174 | 179 | 200 | 172.5 | ||
| 172 | 201 | 192 | 203 | 188 | 195 | 192 | 191 | 213 | 215 | 196.2 |
* Higher rates show better quality of modeling
Interaction similarity scores of the selected HTL epitopes using GalexyPepDock flexible docking server.
| Protein | Epitope | DRB1-0101 | DRB1-0301 | DRB1-0401 | DRB1-1101 | DRB1- 1501 | DRB5-0101 | Average |
|---|---|---|---|---|---|---|---|---|
| S | 139 | 146 | 132 | 132 | 132 | 132 | 135.5 | |
| 124 | 126 | 124 | 126 | 124 | 126 | 125.0 | ||
| 118 | 105 | 118 | 118 | 108 | 118 | 114.1 | ||
| 133 | 123 | 113 | 123 | 113 | 113 | 119.6 | ||
| 135 | 133 | 135 | 133 | 135 | 135 | 134.3 | ||
| 170 | 128 | 128 | 128 | 132 | 128 | 135.6 | ||
| 141 | 129 | 141 | 141 | 141 | 141 | 139.0 | ||
| 148 | 126 | 126 | 126 | 126 | 126 | 129.6 | ||
| 123 | 116 | 120 | 116 | 123 | 120 | 119.6 | ||
| 131 | 131 | 131 | 130 | 130 | 131 | 130.6 | ||
| M | 117 | 113 | 117 | 117 | 117 | 117 | 116.3 | |
| 124 | 124 | 124 | 128 | 124 | 128 | 125.3 | ||
| 169 | 169 | 169 | 139 | 169 | 169 | 164.0 | ||
| 137 | 124 | 125 | 137 | 137 | 137 | 132.8 | ||
| N | 137 | 131 | 137 | 137 | 137 | 131 | 135 | |
| 136 | 133 | 131 | 136 | 131 | 136 | 133.8 | ||
| 127 | 134 | 127 | 127 | 134 | 127 | 129.3 | ||
| 137 | 137 | 137 | 137 | 149 | 137 | 139.0 | ||
| 107 | 107 | 107 | 105 | 105 | 107 | 106.3 | ||
| 142 | 118 | 118 | 118 | 118 | 118 | 122.0 |
* Higher rates show better quality of modeling
Fig 1The suggested epitope constructs: a) the schematic diagram of the LBL epitope construct derived from the S and N proteins of the SARS-CoV-2 linked by KK linker; b) the schematic diagram of the CTL epitope construct derived from the S, M and N proteins of the SARS-CoV-2 linked by AAY linker; c) the schematic diagram of the HTL epitope construct derived from the S, M and N proteins of the SARS-CoV-2 linked by GPGPG linker.
Physicochemical properties of the designed HTL and CTL and LBL epitopes.
| Construct | Molecular weight | Theoretical PI | Positive charge residue | Negative charge residue | Solubility | Stability |
|---|---|---|---|---|---|---|
| LBL-epitope | 36.5 kDa | 10.24 | 63 | 26 | Soluble | Stable |
| CTL-epitope | 28.6 kDa | 9.29 | 13 | 3 | Soluble | Stable |
| HTL-epitope | 49.5 kDa | 9.42 | 42 | 31 | Soluble | Stable |
Fig 2The tertiary structure of the predicted LBL construct: a) 3D prediction of LBL multiepitope construct, b) sequence prediction and conformation scores of each amino acid in LBL multiepitope construct.
Fig 4The tertiary structure of the predicted HTL construct: a) 3D prediction of HTL multiepitope construct, b) sequence prediction and conformation scores of each amino acid in HTL multiepitope construct.
Fig 5Refined characteristics of LBL multiepitope construct: a) Refined 3D prediction of LBL multiepitope construct, b) overall quality of refinement, c) Ramachandran plot.
Fig 7Refined characteristics of HTL multiepitope construct: a) Refined 3D prediction of HTL multiepitope construct, b) overall quality of refinement, c) Ramachandran plot.
Fig 8The peptide-protein docking between LBL construct and TLRs 2, 3 and 4: a) LBL-TLR2 complex with participated residues in interaction, b) LBL-TLR3 complex with participated residues in interaction, c) LBL-TLR4 complex with participated residues in interaction.
Fig 10The peptide-protein docking between HTL construct and TLRs 2, 3 and 4: a) HTL-TLR2 complex with participated residues in interaction, b) HTL-TLR3 complex with participated residues in interaction, c) HTL-TLR4 complex with participated residues in interaction.